
BLA submitted to FDA for BCMA-directed, 2nd-generation bispecific antibody etentamig in R/R myeloma
A Biologics License Application was submitted to the US Food and Drug Administration for the BCMA-directed, 2nd-generation bispecific antibody etentamig for the treatment of relapsed or refractory multiple myeloma, as reported by the drug’s manufacturer, AbbVie.





